Education
About Us
Working with TipRanks
Follow Us
Avita Medical Ltd (RCEL)
:RCEL
RCEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.90 - $14.16
Previous CloseN/A
Volume824.49K
Average Volume (3M)222.44K
Market Cap
$227.20M
Enterprise Value$344.77M
Total Cash (Recent Filing)$26.68M
Total Debt (Recent Filing)$449.48K
Price to Earnings (P/E)―
Beta2.58
Next Earnings
May 08, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.39
Shares Outstanding26,357,542
10 Day Avg. Volume261,712
30 Day Avg. Volume222,440
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.68
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.27
Enterprise Value/Ebitda-6.42
Forecast
1Y Price Target
$16.20Price Target Upside87.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Avita Medical News
PremiumCompany Announcements
Avita Medical Boosts Production with New Agreement
PremiumCompany Announcements
AVITA Medical Reports Transformative Year Amidst Challenges---
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe acquisition of Cohealyx, a collagen-based dermal matrix product, is expected to triple Avita's addressable market in burns.
Product PortfolioAvita's flagship RECELL platform is generating nice traction, as evidenced by the 29% revenue growth performance.
Revenue GrowthAvita is forecasting remarkable revenue growth of 55-65%, a significant acceleration from previous performance, and has outlined plans to achieve key profitability metrics.
Bears Say
Debt AgreementAVITA amended its debt agreement with OrbiMed to relax revenue requirements over the next few quarters, removing a significant perceived overhang on the stock.
---
Ownership Overview
1.24% Insiders
8.47% Mutual Funds
1.55% Other Institutional Investors
79.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCEL FAQ
What was Avita Medical Ltd’s price range in the past 12 months?
Avita Medical Ltd lowest stock price was $6.90 and its highest was $14.16 in the past 12 months.
What is Avita Medical Ltd’s market cap?
Avita Medical Ltd’s market cap is $227.20M.
When is Avita Medical Ltd’s upcoming earnings report date?
Avita Medical Ltd’s upcoming earnings report date is May 08, 2025 which is in 23 days.
How were Avita Medical Ltd’s earnings last quarter?
Avita Medical Ltd released its earnings results on Feb 13, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.429 by -$0.011.
Is Avita Medical Ltd overvalued?
According to Wall Street analysts Avita Medical Ltd’s price is currently Undervalued.
Does Avita Medical Ltd pay dividends?
Avita Medical Ltd does not currently pay dividends.
What is Avita Medical Ltd’s EPS estimate?
Avita Medical Ltd’s EPS estimate is -0.31.
How many shares outstanding does Avita Medical Ltd have?
Avita Medical Ltd has 26,357,542 shares outstanding.
What happened to Avita Medical Ltd’s price movement after its last earnings report?
Avita Medical Ltd reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.429. Following the earnings report the stock price went up 20.387%.
Which hedge fund is a major shareholder of Avita Medical Ltd?
Among the largest hedge funds holding Avita Medical Ltd’s share is Hussman Strategic Advisors Inc. It holds Avita Medical Ltd’s shares valued at 0.
---
Avita Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.20 (87.94% Upside)
$16.20 (87.94% Upside)
Blogger Sentiment
Bullish
RCEL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 42.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $218.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.71%
12-Months-Change
Fundamentals
Return on Equity
-230.96%
Trailing 12-Months
Asset Growth
-28.60%
Trailing 12-Months
Company Description
Avita Medical Ltd
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
---
RCEL Company Deck
---
RCEL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
AVITA Medical's earnings call reflected a transformative year with substantial revenue growth, improved gross profit margins, and a significant increase in total addressable market due to new product launches. However, the company faced challenges with a Q4 revenue shortfall, increased net losses, and higher operating expenses, which balanced the positive achievements.Read More>---
RCEL Revenue Breakdown
99.27% Commercial sales
0.67% Services for emergency preparedness
0.07% Deferred commercial revenue
---
RCEL Stock 12 Month Forecast
Average Price Target
$16.20
▲(87.94% Upside)
Technical Analysis
Best Analysts Covering RCEL
1 Year
1 Year Success Rate
4/15 ratings generated profit
1 Year Average Return
-13.71%
reiterated a buy rating 30 days ago
Copying Josh Jennings's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -13.71% per trade.
---